Venture capital company HBM BioVentures Ltd plans to expand its shareholder base through an IPO. The company intends to issue a limited number of new shares and list all shares on the SWX Swiss Exchange shortly. HBM BioVentures invests globally in emerging companies in the biotechnology and medical technology sectors. The investment focus is emerging private and small-cap public companies that are at varying stages of development. The portfolio includes private companies (59%), public companies originating from the private portfolio (17%), other public companies (11%) and other current assets (13%, including cash of 8%) at this time. It is well diversified in terms of geography, therapeutic areas, the portfolio companies' stage of development and the timing of investments.
Charcoal and natural additives company saw final bids from two banks and one direct lender
VCs including the Swiss Entrepreneurs Fund, BtoV and Ringier Digital Ventures also participated
Around 40 existing and new LPs, including British Patient Capital and the EIF, participated
Fund will invest in buyouts, recapitalisations and carve-outs of both profitable and underperforming businesses